ABSTRACT
BACKGROUND: Very few studies describe group B streptococcal dermo-hypodermitis in newborns. OBJECTIVES: To describe the incidence, clinical characteristics, and course of group B streptococcal dermo-hypodermitis in infants less than 3 months old. PATIENTS AND METHODS: Infants under 3 months of age, hospitalized for group B streptococcal dermo-hypodermitis at Robert Debré University Hospital, Paris, France, and at Orsay Hospital, Orsay, France, between January 2002 and August 2013, were included in a retrospective study. RESULTS: Five infants were included in this study. All the infections occurred late. Dermo-hypodermitis accounted for 7% of the overall late-onset group B streptococcal infections during the same period. Four patients were male and had a risk factor of maternal-fetal infection (prematurity/hypotrophy). Four patients had specific clinical signs of dermo-hypodermitis with septic shock features on admission. One patient had meningitis and associated parotitis. Group B Streptococcus was isolated from blood culture of all patients. Serotype III Streptococcus was identified in four cases. The duration of intravenous antibiotic therapy varied from 7 to 23 days and the total duration of antibiotic therapy was between 14 and 44 days. The progression was favorable for all the infants, with no recurrence. CONCLUSION: Dermo-hypodermitis in infants under 3 months of age is rare but could be an early indicator of group B streptococcal bacteremia and/or sepsis. Early diagnosis of this severe complication and appropriate antibiotic therapy are critical.
Subject(s)
Skin Diseases, Bacterial , Streptococcal Infections , Streptococcus agalactiae , Female , Hospitals , Humans , Incidence , Infant , Infant, Newborn , Male , Retrospective Studies , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/epidemiology , Skin Diseases, Bacterial/therapy , Streptococcal Infections/diagnosis , Streptococcal Infections/epidemiology , Streptococcal Infections/therapyABSTRACT
The cell wall is directly involved in cell growth, and its ability to loosen and rearrange allows for cell expansion through the existing turgor pressure. Thus, information on cell wall deposition and rearrangement can provide insights into the overall plant growth. This chapter describes two methods that can be used to evaluate cell expansion (1) in the model plant Arabidopsis thaliana and (2) the model alga Penium margaritaceum. These methods are further used to screen for small molecules that induce cell growth phenotypic changes affecting cell wall. Identification of such small molecules is beneficial due to their posttranslational mechanism of action that can be controlled in a temporal and spatial manner. Chemical genomics has the ability to overcome issues of genetic redundancy and lethality, which can hinder traditional genetic methods. The identification of small molecules in these screens will provide useful information on plant cell wall biology and overall plant growth.
Subject(s)
Arabidopsis/cytology , Arabidopsis/growth & development , Chlorophyta/cytology , Chlorophyta/growth & development , Genomics/methods , Small Molecule Libraries/chemistry , Arabidopsis/chemistry , Arabidopsis/genetics , Cell Culture Techniques , Cell Wall/metabolism , Chlorophyta/chemistry , Chlorophyta/genetics , Genome, Plant , High-Throughput Screening Assays/methods , Small Molecule Libraries/analysisABSTRACT
No disponible
Subject(s)
Humans , Male , Infant, Newborn , Scrotum/anatomy & histology , Scrotum/pathology , Actins , Actin Capping Proteins/analysis , Scrotum/abnormalities , Dermis/pathologySubject(s)
Scrotum/abnormalities , Humans , Infant, Newborn , Male , Scrotum/pathology , Scrotum/surgeryABSTRACT
No disponible
Subject(s)
Humans , Male , Infant, Newborn , Hamartoma/diagnosis , Scalp/pathology , Skin Neoplasms/diagnosis , Diagnosis, DifferentialABSTRACT
BACKGROUND: The adequate control of phosphataemia is of major importance in end-stage renal disease patients on maintenance dialysis. Recently, lanthanum carbonate (LC) has been added to the phosphate binder armamentarium. To our knowledge, no studies have yet evaluated the usefulness of this drug in uncontrolled hyperphosphataemic patients. METHODS: This was a 6-month prospective observational study. Patients on chronic hemodialysis who had previously failed to achieve serum phosphate control were enrolled. Thirty-four patients (i.e. 11% out of 305 from three dialysis units) met the inclusion criteria. Lanthanum carbonate was introduced and titrated to achieve serum phosphate control, according to the KDOQI guidelines. Clinical targets, gastrointestinal symptoms, and patients' satisfaction with therapy were assessed at baseline and after 6 months. RESULTS: Eight patients (23.5%) were withdrawn from the study due to side effects. In the remaining patients, serum phosphate level significantly decreased from 5.8 to 4.4 mg/dl and calcium-phosphate product also decreased significantly from 55.6 to 41.8 mg(2)/dl(2). The average number of all phosphate binder tablets taken per day was reduced from 6.7 to 4.7. Evaluation scores of dyspeptic symptoms and of patient's satisfaction with therapy also improved: from 7.5 to 5.3 and from 6.6 to 8.1, respectively. CONCLUSIONS: The introduction of LC improved serum phosphate control in over 70% of these "difficult patients". A lower pill burden was also obtained, which might help to simplify treatment and increase patients' compliance. Dyspeptic symptoms and overall satisfaction with treatment also improved.
Subject(s)
Chelating Agents/therapeutic use , Hyperphosphatemia/drug therapy , Kidney Failure, Chronic/blood , Lanthanum/therapeutic use , Phosphates/blood , Aged , Chelating Agents/adverse effects , Dyspepsia/etiology , Female , Humans , Hyperphosphatemia/etiology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Lanthanum/adverse effects , Male , Middle Aged , Patient Satisfaction , Prospective Studies , Renal DialysisABSTRACT
AIM OF THE STUDY: To estimate the percentage of empirical treatments adapted in the bloodstream infections of community and not community origin and to determine the main circumstances in which this initial treatment is not adapted. PATIENTS AND METHODS: Surveillance of bloodstream infections from the laboratories of microbiology of the eight hospitals of the Ile-de-France network, during year 2007. The study concerned the patients hospitalised in medicine, surgery, obstetrics, intensive care, following care and rehabilitation, day hospitalisation, hospitalisation at home, who presented one or several episodes of bloodstream infections. RESULTS: During year 2007, 2013 bloodstream infections were analysed. Only 63.9% of bloodstream infections had an adapted initial antibiotic treatment. Among this proportion of bloodstream infections, an adapted empirical treatment concerned mainly the community episodes, the urinary tract, the pulmonary tract, or maternal-foetal episodes and the maternity ward and pediatrics. The percentage of adapted treatments was superior in the bloodstream infections where were isolated an Enterobacteriaceae, Streptococcus pneumoniae or other streptococci. On the contrary, only a quarter of bloodstream infections due to an Enterobacteriaceae producing BLSE or to a MRSA had received an adapted empirical treatment. CONCLUSION: Only two-thirds of the patients developing a bloodstream infection received an adapted initial antibiotic treatment. This proportion was even lower when it was not about a community origin, in spite of the frequent administration of several anti-infectious molecules or with wide spectrum.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Community-Acquired Infections/epidemiology , Cross Infection/epidemiology , Drug Resistance, Multiple, Bacterial , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/drug therapy , Bacteremia/microbiology , Child , Child, Preschool , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Drug Utilization , Enterobacteriaceae/drug effects , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Female , France/epidemiology , Humans , Incidence , Infant , Inpatients/statistics & numerical data , Male , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Outpatients/statistics & numerical data , Population Surveillance , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Streptococcal Infections/drug therapy , Streptococcal Infections/epidemiology , Streptococcal Infections/microbiology , Streptococcus/drug effects , Streptococcus/isolation & purification , Young AdultABSTRACT
INTRODUCTION: renal glomerular filtration rate on hospital admission in patients presented with an acute coronary syndrome as a predictor for mortality. PATIENTS AND METHODS: The study analysed 290 patients admitted on hospital with an acute coronary syndrome during one year (2003). Renal function was estimated using the renal glomerular filtration rate by the MDRD formula. Patients were stratified in three groups: patients with a GFR > or = 60 ml/min/1,73 m2; n = 186, patients with GFR < 60 or > 30; n = 93 and patients with GFR < 30; n = 11. RESULTS: 66.6% of patients were males and 66.5% were older than 65 years old. 54.5% suffered from hypertension and 39% were diabetics. All patients with GFR < 30 ml/min had an acute coronary syndrome without elevation of ST segment. They were the oldest with a major proportion of previous cardiovascular events as cerebrovascular disease, peripheral vascular disease or myocardial infarction. Diagnostic procedures and treatments were less administered in patients with GFR < 30 ml/min. Although in the univariate analysis demonstrated that hospital mortality was related to GFR < 30 ml/min, sex, ageing, Killip > 1, ventricular function and cTnT elevation, only GFR < 30 ml/min, ageing, heart failure and ventricular dysfunction persisted significant in the multivariate analysis. Hospital mortality was 27.3% in patients with GFR < 30 ml/min, 7.5% in patients with GFR between 30-60 ml/min and 3.8% in patients with a GFR > or = 60 ml/min. Mortality after two years follow up was 27.3% in patients with GFR < 30 ml/min, 20.4% in patients with GFR between 30-60 ml/min and 10.2% in patients with a GFR > or = 60 ml/min. Mortality (hospital mortality and after two years of follow up) was increased in patients with GFR< 30 ml/min, ageing, heart failure and diabetes after adjusted for other prognostic factors. CONCLUSIONS: A reduced glomerular filtration rate is an independent risk factor for mortality in patients with an acute coronary syndrome. Estimation of the renal glomerular filtration rate might be used as prognostic value in these patients.
Subject(s)
Acute Coronary Syndrome/complications , Acute Coronary Syndrome/mortality , Renal Insufficiency/complications , Renal Insufficiency/mortality , Acute Coronary Syndrome/physiopathology , Aged , Disease Progression , Female , Glomerular Filtration Rate , Humans , Male , Prognosis , Renal Insufficiency/physiopathologyABSTRACT
Introducción: determinar el filtrado glomerular al ingreso como predictor de mortalidad tras un Síndrome Coronario Agudo (SCA). Pacientes y método: se analizaron 290 pacientes que ingresaron por SCA durante el año 2003. Se valoró la función renal al ingreso mediante la fórmula de estimación del Filtrado Glomerular (FG) MDRD. Se estratificaron en tres grupos: pacientes con FG ≥60 ml/min/1,73 m2; n = 186, pacientes con FG <60 y >_30; n = 93 y pacientes con FG <30; n = 11. Resultados: todos los pacientes con FG <30 ml/min presentaron un SCA sin elevación del segmento ST, los cuales eran de edad más avanzada con mayor prevalencia de eventos cardiovasculares previos (accidente vascular cerebral, de arteriopatía periférica, y de infarto de miocardio). La realización de pruebas diagnósticas fue menor. La mortalidad hospitalaria fue del 27,3% en los pacientes con FG <30 ml/min, 7,5% en los pacientes con FG entre 30 y 60 ml/min, y del 3,8% en los pacientes con FG ≥60 ml/min. Tras dos años de seguimiento, la mortalidad fue del 27,3% en los pacientes con FG <30 ml/min, del 20,4% en los pacientes con FG entre 30 y 60 ml/min, y del 10,2% con FG ≥60 ml/min. Al ajustar por otras variables pronósticas, los pacientes con FG <30 ml/min presentaron una mayor mortalidad tanto durante el ingreso como en el seguimiento a dos años. Conclusiones: la reducción del FG es un factor de riesgo independiente de mortalidad tras un SCA. El uso de las fórmulas de estimación del FG en el seguimiento de dichos pacientes tiene valor pronóstico (AU)
Introducción: determinar el filtrado glomerular al ingreso como predictor de mortalidad tras un Síndrome Coronario Agudo (SCA). Pacientes y método: se analizaron 290 pacientes que ingresaron por SCA durante el año 2003. Se valoró la función renal al ingreso mediante la fórmula de estimación del Filtrado Glomerular (FG) MDRD. Se estratificaron en tres grupos : pacientes con FG >_60 ml/min/1,73 m2; n = 186, pacientes con FG <60 y >_30; n = 93 y pacientes con FG <30; n =11. Resultados: todos los pacientes con FG <30 ml/min presentaron un SCA sin elevación del segmento ST, los cuales eran de edad más avanzada con mayor prevalenc ia de eventos cardiovasculares previos (accidente vascular cerebral , de arteriopatía periérica, y de infarto de miocardio) . La realización de pruebas diagnósticas fue menor. La mortalidad hospitalaria fue del27,3% en los pacientes con FG <30 ml/min, 7,5% en los pacientes con FG entre 30 y 60 ml /min, y del 3,8% en los pacientes con FG >_60 ml/min. Tras dos años de seguimiento, la mortalidad fue del 27,3% en los pacientes con FG <30 ml/min, del 20,4% en los pacientes con FG entre 30 y 60 ml /min, y del 10,2% con FG >_60ml /min. Al ajustar por otras variables pronósticas , los pacientes con FG <30 ml /min presentaron una mayor mortalidad tanto durante el ingreso como en el seguimiento a dos años . Conclusiones : la reducción del FG es un factor de riesgo independiente de mortalidad tras un SCA. El uso de las fórmulas de estimación del FG en el seguimiento de dichos pacientes tiene valor pronóstico (AU)
Subject(s)
Humans , Renal Insufficiency, Chronic/mortality , Acute Coronary Syndrome/complications , Severity of Illness Index , Glomerular Filtration Rate , Survival Rate , Risk Factors , Comorbidity , Hospital MortalityABSTRACT
No disponible
No disponible
Subject(s)
Humans , Blood Vessel Prosthesis , Renal Insufficiency, Chronic/therapy , Polyurethanes , Renal DialysisABSTRACT
The mechanism of the analgesic action of acetaminophen involves the serotonergic system. This study explores how acetaminophen interferes with serotonergic descending pain pathways. Eighteen rapid metabolizers of tropisetron were included in this double-blind cross-over study. After ethical approval, the healthy volunteers took 1 g oral acetaminophen (A) or placebo (p) combined with either the 5-HT3 antagonist tropisetron (T) (5 mg) or saline, intravenously, at weekly intervals. Mechanical pain thresholds, determined before and after a cold pressor test (CPT), were repeated seven times during the three post-dosing hours, and area under the concentration-time curves (AUCs) of the three treatments were compared. After CPT, AUC (%*min) of Ap (1,561+/-429) was larger than before CPT (393+/-382, P<0.05); these effects were totally inhibited by tropisetron. Acetaminophen reinforces descending inhibitory pain pathways; it suggests a supraspinal target for acetaminophen's antinociceptive action. This study also confirmed that there is a central serotonergic mechanism of action for acetaminophen that is not stimulus-dependent.
Subject(s)
Acetaminophen/pharmacology , Acetaminophen/therapeutic use , Pain Measurement/drug effects , Pain/drug therapy , Pyramidal Tracts/drug effects , Adult , Area Under Curve , Cross-Over Studies , Double-Blind Method , Humans , Male , Pain/physiopathology , Pain Measurement/methods , Pain Threshold/drug effects , Pain Threshold/physiology , Pyramidal Tracts/physiologyABSTRACT
UNLABELLED: Calcific uraemic arteriolopathy, also named calciphylaxis, is a rare but serious disorder characterized by medial mural calcification of small vessel leading to tissue ischaemia. It most commonly occurs in end stage renal disease patients on dialysis or recently received renal transplant with chronic nephropathy allograft. The pathogenesis of calciphylaxis is poorly understood. Abnormalities in mineral metabolism are clearly involved, but the specific factors that induces this disorder are not completely known. OBJECTIVES: Describe the main clinical features, outcomes and follow up of all calciphylaxis cases recorded in our dialysis unit in order to analyse the incidence, the main biologic parameters and the therapeutic background in which calciphylaxis appeared. MATERIAL AND METHODS: We performed a descriptive study about all the calciphylaxis cases diagnosed at our dialysis unit between the years 1991 and 2005. RESULTS: 8 cases, 6 women. Mean age: 65.3 years. All the patients were on haemodialysis treatment (one previous renal transplant). Mean time on dialysis was 76.6 months. Cumulative incidence was 1.17%. The principal end stage renal disease aethiology was neprhoangioeslerosis in four patients. Secondary hiperparatyrhoidism was present in 4 patients and 2 of them had been paratyrhoidectomized previously. A second cutaneous biopsy was needed for correct diagnosis in 3 patients. Calciphylaxis distal lesions were present in 7 patients. Two cases required urgent paratyrhoidectomy in order to control calciphylaxis. Only in 2 cases a Ca x P product > 60 mg/dL was present and 3 cases had PTHi values higher than 300 pg/mL. Calcium phosphate binders and vitamin D were present in 2 and 4 cases, respectively. One patient with proximal calciphylaxis died due to skin injury infection. CONCLUSIONS: Calciphylaxis is a rare disorder but not exceptional, related to end stage renal disease patients. The diagnosis requires a high clinical suspicion, being sometimes difficult to distinguish from other entities in spite of pathological study. Proximal distribution of calciphylaxis had worst prognostic. Metabolic disorders and therapeutics background were not different from other patients included in dialysis treatment.
Subject(s)
Calciphylaxis , Adult , Aged , Calciphylaxis/diagnosis , Calciphylaxis/epidemiology , Calciphylaxis/therapy , Female , Humans , Incidence , Male , Middle AgedABSTRACT
We report a case of a 49 year old man, diagnosed soon after the outcome of casual proteinuria, of AA-type amyloidosis in relation to small and medium vessel cutaneous vasculitis without systemic involvement. This combination is a rare entity and only two cases of cutaneous hypersensibility vasculitis complicated with AA-type amyloidosis had been reported. We describe the results of the use of several immunosuppressive drugs during four years follow up with temporally total remission of the disease.
Subject(s)
Amyloidosis/etiology , Kidney Diseases/etiology , Skin/blood supply , Vasculitis/complications , Amyloidosis/pathology , Humans , Kidney Diseases/pathology , Male , Middle Aged , Vasculitis/pathologyABSTRACT
La arteriolopatía urémica calcificante, también conocida como calcifilaxis, es una entidad caracterizada por la presencia de áreas de necrosis isquémica junto con extensas calcificaciones de la capa media de las arteriolas dermoepidérmicas. Fundamentalmente se desarrolla en pacientes con insuficiencia renal en diálisis o trasplantados con disfunción del injerto. Aunque las alteraciones propias del estado urémico y del metabolismo calcio-fósforo son importantes, su etiopatogenia es compleja; siendo los mecanismos desencadenantes poco conocidos. Objetivos: Describir las formas de presentación y evolución de los casos de calcifilaxis diagnosticados en nuestra unidad de diálisis. Calcular la incidencia y analizar el contexto biológico y terapéutico previo al episodio de calcifilaxis. Material y métodos: Análisis descriptivo de todos los casos de calcifilaxis diagnosticados en nuestra unidad durante el período comprendido entre 1991-2005. Resultados: 8 casos, 6 mujeres. Edad media: 65,3 años. Todos los pacientes incluidos en programa de Hemodiálisis (1 trasplante renal previo). Tiempo medio en diálisis de 76,6 meses. La incidencia acumulada fue de 1,17%. La principal etiología de la IRC fue la Nefroangioesclerosis (4 pacientes). Existía antecedentes de hiperparatiroidismo secundario en 4 pacientes, con paratiroidectomía previa en 2 de ellos. En 3 pacientes el diagnóstico requirió una segunda biopsia cutánea. La distribución de las lesiones fue distal en 7 casos. En 2 casos se practicó paratiroidectomía urgente para el control de las lesiones. Tan sólo 2 casos presentaban producto Calcio-fósforo > 60 mg/dL y 3 casos cifras de PTHi > 300 pg/mL. 2 casos tomaban quelantes cálcicos y 4 suplementos de vitamina D. Un paciente con distribución proximal de las lesiones fue exitus por sobreinfección de las mismas. Conclusiones: La calcifilaxis es un proceso infrecuente. El diagnóstico requiere de una alta sospecha clínica, siendo en ocasiones difícil de distinguir de otros procesos. La localización a nivel proximal confiriere un peor pronóstico a las lesiones. Las alteraciones metabólicas y conductas terapéuticas son indistinguibles de las que presentan el resto de pacientes sometidos a diálisis
Calcific uraemic arteriolopathy, also named calciphylaxis, is a rare but serious disorder characterized by medial mural calcification of small vessel leading to tissue ischaemia. It most commonly occurs in end stage renal disease patients on dialysis or recently received renal trasplant with chronic nephropathy allograft. The pathogenesis of calciphylaxis is poorly understood. Abnormalities in mineral metabolism are clearly involved, but the specific factors that induces this disorder are not completely known. Objectives: Describe the main clinical features, outcomes and follow up of all calciphylaxis cases recorded in our dialysis unit in order to analise the incidence, the main biologic parameters and the therapeutic background in wich calciphylaxis appeared. Material and methods: We performed a descriptive study about all the calciphylaxis cases diagnosed at our dialysis unit beetwen the years 1991 and 2005. Results: 8 cases, 6 women. Mean age: 65.3 years. All the patients were on haemodialysis treatment (one previous renal transplant). Mean time on dialysis was 76.6 months. Cumulative incidence was 1.17%. The principal end stage renal disease aethiology was neprhoangioeslerosis in four patients. Secondary hiperparatyrhoidism was present in 4 patients and 2 of them had been paratyrhoidectomized previously. A second cutaneus biopsy was needed for correct diagnosis in 3 patients. Calciphylaxis distal lesions were present in 7 patients. Two cases required urgent paratyrhoidectomy in order to control calciphylaxis. Only in 2 cases a Ca x P product > 60 mg/dL was present and 3 cases had PTHi values higher than 300 pg/mL. Calcium phospate binders and vitamin D were present in 2 and 4 cases, respectively. One patient with proximal calciphylaxis died due to skin injury infection. Conclusions: Calciphylaxis is a rare disorder but not exceptional, related to end stage renal disease patients. The diagnosis requires a high clinical suspicion, beeing sometimes dificult to distinguish from other entities in spite of pathological study. Proximal distribution of calciphylaxis had worst prognostic. Metabolic disorders and therapeutics background were not different from other patients included in dialysis treatmen
Subject(s)
Humans , Calciphylaxis/physiopathology , Renal Insufficiency, Chronic/complications , Renal Dialysis , Arterioles/physiopathology , Calciphylaxis/epidemiologyABSTRACT
Presentamos el caso de un paciente de 49 años de edad, diagnosticado a raíz del hallazgo de proteinuria aislada, de amiloidosis AA asociada a vasculitis de mediano y pequeño calibre con afectación exclusivamente cutánea. Esta asociación es muy poco frecuente y sólo se han descrito dos casos de vasculitis por hipersensibilidad y amiloidosis AA. Comentamos la evolución a lo largo de cuatro años en que ha sido tratado con distintos inmunosupresores, consiguiendo algún período de remisión completa de la enfermedad
We report a case of a 49 years old man, diagnosed soon after the outcome of casual proteinuria, of AA-type amyloidosis in relation to small and medium vessel cutaneous vasculitis without systemic involvement. This combination is a rare entity and only two cases of cutaneous hipersensiblility vasculitis complicated with AA-type amyloidosis had been reported. We describe the results of the use of several inmunossupressive drugs during four years follow up with temporally total remission of the disease
Subject(s)
Male , Middle Aged , Humans , Amyloidosis/complications , Vasculitis, Leukocytoclastic, Cutaneous/complications , Immunosuppressive Agents/therapeutic use , Proteinuria/etiology , Serum Amyloid A Protein/analysisABSTRACT
Parathyroid carcinoma (PC) is an infrequent disease with a subtle initial presentation and a variable course, necessitating a high index of suspicion to make the correct diagnosis. In chronic failure patients on haemodialysis it becomes even more difficult to suspect this entity since the high prevalence of secondary hyperparathyroidism(SHP). Two patients with PC out of a series of 160 patients with moderate-to-severe SHP submitted for parathyroidectomy are reported. Their clinical features are compared with those of the twenty-two cases previously reported in the literature with a discussion of this pathology. Patients with PC showed higher blood levels of iPTH, total calcium, phosphate and total alkaline phosphatase than the SHP population. The final diagnosis of PC was made after histological study revealing capsular or blood vessel invasion.